Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pedro R. Lowenstein"'
Autor:
Sriram Venneti, Jason Heth, Sandra Camelo-Piragua, Karin M. Muraszko, Michelle M. Kim, Theodore S. Lawrence, Andrew P. Lieberman, Larry Junck, Maria G. Castro, Denise Leung, Daniel A. Orringer, Daniel R. Wahl, Pedro R. Lowenstein, Yoshie Umemura, Andrea Comba, Paul E. McKeever, Aaron Mammoser, Shawn L. Hervey-Jumper, David Altshuler, Oren Sagher
Publikováno v:
Journal of Clinical Oncology. 37:2019-2019
2019 Background: This is the initial report on a first in human Phase I dose escalation trial of the combination of two adenoviral vectors expressing HSV1-TK or Flt3L for the treatment of newly diagnosed, resectable malignant gliomas. The absence of
Autor:
Pedro R. Lowenstein
Publikováno v:
Journal of Clinical Oncology. 28:4670-4673
Autor:
Tom Mikkelsen, Daniel A. Orringer, Ana C. deCarvalho, Carl Koschmann, Pedro R. Lowenstein, Sebastien Motsch, Sandra Camelo-Piragua, Gregory J. Baker, W. S. Nichols, Anda Alexandra Calinescu, Serguei Bannykh, Maria G. Castro, Yohei Mineharu, Viveka Nand Yadav
Publikováno v:
Journal of Clinical Oncology. 32:2057-2057
2057 Background: Malignant glioma cells use distinct brain structures for tumor growth and invasion. However, the cellular mechanisms and biological consequences of malignant glioma growth patterni...
Autor:
H. Assi, Serguei Bannykh, G. King, Maria G. Castro, M. Candolfi, Yohei Mineharu, Kader Yagiz, Pedro R. Lowenstein, K. Kroeger, W. Xiong
Publikováno v:
Journal of Clinical Oncology. 28:2093-2093
2093 Background: Conditional-cytotoxic/immuno-stimulatory therapy using adenoviruses expressing HSV1-thymidine kinase (Ad-TK) and fms-like tyrosine kinase 3 ligand (Ad-Flt3L) achieves long term sur...